Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

Daperno, Marco; D’Haens, Geert R.; Assche, Gert Van; Baert, Filip; Bulois, P.; Maunoury, V.; Sostegni, R.; Rocca, Rodolfo; Pera, A.; Gevers, Annemie

doi:10.1016/s0016-5107(04)01878-4

Cited by 1,380 publications

(943 citation statements)

References 14 publications

Supporting

Mentioning

860

Contrasting

Unclassified

Order By: Relevance

“…Two secondary measures of endoscopic disease activity were also calculated: the Crohn's Disease Endoscopic Index of Severity (CDEIS) 28 and the Simple Endoscopic Score for Crohn's Disease (SES-CD), 29 to ensure robustness of the Rutgeerts score.…”

Section: Endoscopic Visual Assessmentmentioning

confidence: 99%

“…32 The outcomes observed using other endoscopic scoring systems provide support for the primary measure used in this study (Rutgeert's score). Although the Crohn's Disease Endoscopic Index of Severity (CDEIS) 28 and the Simple Endoscopic Score for Crohn's Disease (SES-CD) 29 are not specific for the post-operative setting, they were used in the context of removal of all macroscopic disease.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery

et al. 2015

View full text Add to dashboard Cite

and PV Desmond have no conflicts of interest to declare. P De Cruz has received travel grant support from Abbott and Schering-Plough. MA Kamm has acted as an advisor to Abbott and Janssen, has received research support from Abbott, and has acted as a speaker at symposiums sponsored by Abbott and Janssen. A Hamilton has received an educational grant from Abbott. D Liew has served on advisory boards and received research grants from Abbott. IC Lawrance has been on an advisory board for Abbott and Janssen, a speaker for Abbott and Janssen, and has held research and travel grants from Abbott and Janssen. JM Andrews has been an advisory board member for both Janssen and Abbott, spoken for both Abbott and Janssen, received research funds from both Abbott and Janssen, and received travel grants from both Abbott and Janssen. PA Bampton has been on advisory boards for Janssen and Abbott, has received research funding from Abbott, and travel sponsorship from both Abbott and Janssen. PR Gibson has received consulting fees from Abbott, Janssen, and Schering-Plough; research support from Abbott; and payments for lectures from Abbott and Janssen. FA Macrae has been on an advisory board to Janssen, has received travel grants from Abbott, and has received clinical research support from Janssen, Abbott and MSD. W Selby has been on an advisory board for Abbott. SJ Bell has received travel assistance from Abbott. SJ Brown has received travel support and speaker fees from both Abbott and Janssen. WR Connell has been on advisory board for Janssen and a speaker for Abbott and Janssen. AS Day has been an M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT advisor to Janssen. RB Gearry has been on an advisory board for Abbott and Janssen, a speaker for Abbott and Janssen, and held research, educational and travel grants from Abbott and Janssen.

show abstract

Section: Endoscopic Visual Assessmentmentioning

confidence: 99%

Section: Accepted Manuscriptmentioning

confidence: 99%

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery

et al. 2015

View full text Add to dashboard Cite

show abstract

“…21 Complete endoscopic healing was defined as an ulceration sub score of 0 in all segments using the Crohn's disease simple endoscopic score (SES-CD). 22 Partial endoscopic healing was defined as an ulceration sub score of no more than 1 in ≤ 2 segments of all segments examined. Patients were defined free from active disease if there was no ulceration on upper GI endoscopy, colonoscopy and small bowel imaging assessed by the adjudication committee.…”

Section: Endpoints and Outcomementioning

confidence: 99%

Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial

Lindsay

Allez

Clark

et al. 2017

The Lancet Gastroenterology & Hepatology

View full text Add to dashboard Cite

BACKGROUND The randomised controlled ASTIC trial showed no benefit of mobilisation and autologous haematopoietic stem-cell transplantation (HSCT) compared with mobilisation followed by conventional therapy using a stringent primary endpoint (steroid-free clinical remission for 3 months with no endoscopic or radiological evidence of intestinal inflammation) in patients with treatment-refractory Crohn's disease. We now assess HSCT in patients enrolled in the ASTIC trial using endpoints that are traditional for clinical trials in Crohn's disease, and identify factors that predict benefit or harm. METHODS Patients who underwent mobilisation and were randomly assigned to conventional therapy in the ASTIC trial were offered HSCT at 1 year and underwent complete assessment for a further year. We report analyses of the combined cohort of patients who underwent HSCT at any time during the ASTIC trial programme. The primary outcome for this analysis was 3-month steroid-free clinical remission at 1 year after HSCT (Crohn's Disease Activity Index [CDAI] <150). We also examined the degree of endoscopic healing at 1 year. Multivariate analysis was performed to identify factors associated with achieving the primary endpoint by using logistic regression, and factors associated with experiencing a serious adverse event using Poisson regression. Participants were not masked to treatment, but the adjudication panel that reviewed radiology and endoscopy was masked to allocation and visits. All patients who underwent HSCT and had data available at baseline and 1-year follow-up were included in the primary and safety analysis. This trial is registered with ClinicalTrials.gov, number NCT00297193. FINDINGS Between June 28, 2007, and Sept 1, 2011, 45 patients were enrolled in the ASTIC trial from 11 European transplant units. 23 patients were randomly assigned to immediate HSCT, and 22 patients were assigned to mobilisation followed by conventional care. After completion of the ASTIC trial, 17 patients from the conventional care group received HSCT. In the combined cohort, data were available for 40 patients at baseline and 38 patients at 1 year after HSCT (one patient died, one withdrew). At 1 year after HSCT, 3-month steroid-free clinical remission was seen in 13 (38%, 95% CI 22-55) of 34 patients with available data for the whole year. Complete endoscopic healting was noted in 19 (50%, 34-66) of 38 patients. On multivariate analyses, factors associated with the primary outcome were short disease duration (odds ratio [OR] 0·64, 95% CI 0·41-0·997 per year; p=0·048) and low baseline CDAI (0·82, 0·74-0·98 per 10 units; p=0·031). 76 serious adverse events occurred in 23 of 40 patients with available data. The most common serious adverse event was infection, most of which were treatment related. Smoking and perianal disease at baseline were independent factors associated with the number of serious adverse events (OR 3·07 [95% CI 1·75-5·38; p=0·0001] for smoking and 3·97 [2·17-7·25; p<0·0001] for perianal disease) on multivariate...

show abstract

“…Endoscopic biopsies were taken at sites of active inflammation adjacent to ulcerations before and 10 weeks after IFX therapy. The endoscopic assessment of disease activities for mucosal inflammation was performed using the simple endoscopic score for Crohn's disease (SES-CD) [22]. Endoscopic biopsy samples from 18 healthy volunteers paired for sex and age (11 male and seven female, age 21-49 years) were also taken for comparison.…”

Section: Patients and Sample Collectionmentioning

confidence: 99%

Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease

Liu

Xia

et al. 2013

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

Cited by 1,380 publications

References 14 publications

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery

Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial

Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease

Contact Info

Product

Resources

About